226 related articles for article (PubMed ID: 29782365)
1. Utilization of an Alternative Docetaxel-based Intraperitoneal Chemotherapy Regimen in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma: A Continued Need for Ovarian Cancer Patients.
Becker DA; Leath CA; Walters-Haygood CL; Smith BQ; Bevis KS
Am J Clin Oncol; 2019 Jan; 42(1):12-16. PubMed ID: 29782365
[TBL] [Abstract][Full Text] [Related]
2. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
[TBL] [Abstract][Full Text] [Related]
3. Safety and outcome of patients treated with a modified outpatient intraperitoneal regimen for epithelial ovarian, primary peritoneal or fallopian tube cancer.
Battelli C; Campo M; Buss MK; Awtrey CS; Konstantinopoulos PA
Chemotherapy; 2013; 59(4):251-9. PubMed ID: 24457572
[TBL] [Abstract][Full Text] [Related]
4. Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: a gynecologic oncology group study.
Dizon DS; Sill MW; Gould N; Rubin SC; Yamada SD; Debernardo RL; Mannel RS; Eisenhauer EL; Duska LR; Fracasso PM
Gynecol Oncol; 2011 Nov; 123(2):182-6. PubMed ID: 21820161
[TBL] [Abstract][Full Text] [Related]
5. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
Berry E; Matthews KS; Singh DK; Buttin BM; Lurain JR; Alvarez RD; Schink J
Gynecol Oncol; 2009 Apr; 113(1):63-7. PubMed ID: 19201457
[TBL] [Abstract][Full Text] [Related]
6. A phase I study with an expanded cohort to assess feasibility of intravenous docetaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with previously untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Gould N; Sill MW; Mannel RS; Thaker PH; DiSilvestro PA; Waggoner SE; Yamada SD; Armstrong DK; Fracasso PM; Walker JL
Gynecol Oncol; 2012 Dec; 127(3):506-10. PubMed ID: 22943879
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer.
Landrum LM; Hyde J; Mannel RS; McMeekin DS; Moore KN; Walker JL
Gynecol Oncol; 2011 Sep; 122(3):527-31. PubMed ID: 21664657
[TBL] [Abstract][Full Text] [Related]
8. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of intravenous oxaliplatin and intraperitoneal docetaxel in recurrent ovarian cancer.
Taylor SE; Petschauer JS; Donovan H; Schorzman A; Razo J; Zamboni WC; Edwards RP; Zorn KK
Int J Gynecol Cancer; 2019 Jan; 29(1):147-152. PubMed ID: 30640697
[TBL] [Abstract][Full Text] [Related]
10. Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009.
Tiersten AD; Liu PY; Smith HO; Wilczynski SP; Robinson WR; Markman M; Alberts DS
Gynecol Oncol; 2009 Mar; 112(3):444-9. PubMed ID: 19138791
[TBL] [Abstract][Full Text] [Related]
11. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intraperitoneal carboplatin and intraperitoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
Gould N; Sill MW; Mannel RS; Thaker PH; Disilvestro P; Waggoner S; Yamada SD; Armstrong DK; Wenzel L; Huang H; Fracasso PM; Walker JL
Gynecol Oncol; 2012 Apr; 125(1):54-8. PubMed ID: 22155262
[TBL] [Abstract][Full Text] [Related]
12. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
Esselen KM; Rodriguez N; Growdon W; Krasner C; Horowitz NS; Campos S
Gynecol Oncol; 2012 Oct; 127(1):51-4. PubMed ID: 22659193
[TBL] [Abstract][Full Text] [Related]
13. Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.
Schlappe BA; Mueller JJ; Zivanovic O; Gardner GJ; Long Roche K; Sonoda Y; Chi DS; O'Cearbhaill RE
Gynecol Oncol; 2016 Jul; 142(1):13-18. PubMed ID: 27189456
[TBL] [Abstract][Full Text] [Related]
14. Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Ohishi R; Hasegawa K; Goto T; Fujiwara K
Int J Gynecol Cancer; 2012 Jan; 22(1):70-5. PubMed ID: 22146766
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
[TBL] [Abstract][Full Text] [Related]
16. Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancer.
Seamon LG; Carlson MJ; Richardson DL; Cohn DE; Fowler JM; Copeland LJ; O'Malley DM
Int J Gynecol Cancer; 2009 Oct; 19(7):1195-8. PubMed ID: 19823054
[TBL] [Abstract][Full Text] [Related]
17. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.
Katsumata N; Yasuda M; Isonishi S; Takahashi F; Michimae H; Kimura E; Aoki D; Jobo T; Kodama S; Terauchi F; Sugiyama T; Ochiai K;
Lancet Oncol; 2013 Sep; 14(10):1020-6. PubMed ID: 23948349
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of the number of postoperative intraperitoneal chemotherapy cycles for patients with advanced epithelial ovarian cancer.
Suidan RS; Zhou Q; Iasonos A; O'Cearbhaill RE; Chi DS; Long Roche KC; Tanner EJ; Denesopolis J; Barakat RR; Zivanovic O
Int J Gynecol Cancer; 2015 May; 25(4):599-606. PubMed ID: 25664437
[TBL] [Abstract][Full Text] [Related]
19. Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer.
Micha JP; Goldstein BH; Rettenmaier MA; Mattison J; Graham C; Birk CL; Brown JV
Gynecol Oncol; 2004 Sep; 94(3):719-24. PubMed ID: 15350364
[TBL] [Abstract][Full Text] [Related]
20. Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer.
Cheng M; Lee HH; Chang WH; Lee NR; Huang HY; Chen YJ; Horng HC; Lee WL; Wang PH
Int J Environ Res Public Health; 2019 Nov; 16(23):. PubMed ID: 31795359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]